Lupin signs exclusive licensing pact with Neopharmed for Plasil in Philippines and Brazil

This agreement will enhance Lupin’s gastroenterology portfolio and expand its presence in emerging markets

Gilead’s new HIV therapy shows promising Phase 3 results

The study found BIC/LEN to be statistically non-inferior to BIKTARVY, Gilead’s current standard-of-care therapy

Takeda joins BaseLaunch to boost early-stage biotech ventures in Europe

BaseLaunch has supported 27 biotech companies across multiple modalities and indications

Ambros Therapeutics launches with $125 million to advance breakthrough therapy for rare pain disorder

The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1

SABIC launches first fluorine-free polycarbonate resin to boost medical device safety

The NP resin portfolio, indicated by its UL746G-certified prefix, equips manufacturers across industries to meet increasingly stringent regulatory and performance standards

ystral expands in India with new Bangalore facility, boosting team & local production

The expansion includes a larger technical and service team and increased local procurement

Lupin receives positive CHMP opinion for biosimilar Ranibizumab

Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A

Godavari Biorefineries launches US biotech arm to advance novel cancer therapies

The move strengthens GBL’s clinical-stage presence in the United States

Merck’s KEYTRUDA–Padcev combo delivers survival gains in Phase 3 bladder cancer trial

Astellas & Pfizer report breakthrough Phase 3 results in muscle-invasive bladder cancer

The combination also outperformed chemotherapy on another important secondary endpoint